Calico

While it is impossible to escape mortality entirely, Google-backed life sciences company Calico reportedly has plans to launch a $1.5 billion research and development center with an underlying goal of extending the lifespan of humans. The future San Francisco-based aging research center, to be built in partnership with biopharmaceutical company AbbVie, is said to focus on drug discovery and development for diseases such as neurodegeneration and cancer. 

“This particular moon shot won’t come cheap,” reports Re/code. “Calico and AbbVie said they are splitting costs equally by each committing $250 million upfront, with an option to add $500 million more. Calico is to lead the first five years of early development, with AbbVie managing late-stage development and commercialization.”

According to Calico CEO Arthur D. Levinson, the former CEO of Genentech, his company will work to develop life-enhancing therapies for individuals with age-related diseases. Levinson replaced the late Steve Jobs as Apple’s chairman of the board in late 2011, a position that he has held since. Levinson has also been the chairman of Genentech since 1999 and sits on a number of other health and science related boards.

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

2 Responses to “Google-backed Calico launching $1.5 billion research center with goal of extending life”

  1. Fantastic news, glad to see some serious investment being put into this area, especially from Google. Hopefully they’re in communication with Aubrey de Grey at the SENS Foundation too!